Navigation Links
OrthoAccel Technologies, Inc. Announces Appointment of New Chief Financial Officer
Date:12/5/2012

HOUSTON, Dec. 5, 2012 /PRNewswire/ -- Pamela Westbrook has been named Chief Financial Officer, Vice President Finance & Administration for OrthoAccel Technologies (OrthoAccel®). In this position, she will oversee a broad range of corporate matters, including investor relations, financial reporting, treasury and taxation, information technology and organizational development for the company's global operations.

Ms. Westbrook has over 25 years of experience in finance and administration, primarily in the medical device industry. For the past five years, she has provided financial consulting services for a number of privately-owned start-up medical device companies, including OrthoAccel.  Prior to that, she served as CFO at Cyberonics, Inc. and the Physicians Resource Group. In addition, she was Vice President, Finance for SulzerMedica USA, Inc, and Vice President, Controller for Sulzer Carbomedics, Inc. She also held a Director-level position with Intermedics, Inc.

She graduated Cum Laude in Business Administration – Accounting from the University of Texas, Austin, and has been certified by the Texas State Board of Public Accountancy.

"We are absolutely delighted to welcome someone as qualified, experienced and skilled as Pam to OrthoAccel," says OrthoAccel CEO Mike Lowe. "As our business continues to grow both domestically and internationally, it's essential for our progress to be guided by sound financial principals and insight. We're entirely confident that Pam will provide those benefits. It's great to have her on board."

Ms. Westbrook joins OrthoAccel at the company's new offices in Bellaire, located in the Houston-Sugar Land metro area.

About OrthoAccel® Technologies, Inc.

Based in Houston, Texas, OrthoAccel Technologies, Inc. is a privately owned medical device company currently engaged in the development, manufacturing, and marketing of products to enhance dental care and orthodontic treatment.

OrthoAccel developed and sells AcceleDent™, the first FDA-cleared clinical approach to safely accelerate orthodontic tooth movement by applying precisely calibrated micropulses as a complement to existing orthodontic treatment. More information can be found at www.acceledent.com or requested via info@orthoaccel.com.


'/>"/>
SOURCE OrthoAccel Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
2. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
3. Radiation Control Technologies, Inc. Announces Exclusive License to Two Patents from the National Institutes of Health
4. CanCHEW Bio-Technologies, a Medical Marijuana Inc. Product, Dr. George Anastassov Appeared on Small Cap Voice Internet Radio Program To Discuss The CanCHEW Advantage
5. Drug Discovery Technologies, BCC Research
6. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
7. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
8. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
9. Misonix Announces New Distribution Agreement For Panama
10. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... 2016 , ... Research has shown that building shame resilience ... and level of relapse. , At the 2016 iaedp Symposium, the ... the critical tasks of the recovery phase and beyond including relapse prevention and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
(Date:2/5/2016)... City, UT (PRWEB) , ... February 05, 2016 , ... ... Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist in ... Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV show, ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
Breaking Medicine News(10 mins):